Steinhoff Jeffrey P, Kolli Sahiti, Mattlin Meredith P, Schlauch Daniel, Braisted Andrew T, Reddy Sreenath V, Klodell Charles, Dewey Todd, Fontana Gregory P
Echocardiography Department, HCA Florida Largo Hospital, HCA Healthcare, Largo, Florida.
Genospace, HCA Healthcare, Boston, Massachusetts.
Ann Thorac Surg Short Rep. 2024 Mar 28;2(3):347-350. doi: 10.1016/j.atssr.2024.02.019. eCollection 2024 Sep.
Current treatment guidelines for infective endocarditis focus on left-sided infective endocarditis. Because right-sided infective endocarditis has different presentations and outcomes, it is crucial to further delineate surgical outcomes for isolated tricuspid valve endocarditis (TVE).
This retrospective study reviewed 374 surgically treated patients with isolated TVE from January 2012 through April 2022 who underwent isolated tricuspid valve surgical procedures. Primary outcomes were in-hospital mortality, permanent pacemaker need, and postsurgical inotropic support.
The in-hospital mortality was 4% (n = 15). Patients with liver disease had 3.81-times higher odds of death vs no liver disease (odds ratio [OR], 3.81; 95% CI, 1.22-12.17). A pacemaker was required in 17% of patients without a prior pacemaker, which was 4.07 times the odds with tricuspid valve replacement (OR, 4.07; 95% CI, 1.72-11.60) vs tricuspid valve repair. Each yearly increase in patient age demonstrated lower odds of permanent pacemaker requirement by 7% (OR, 0.93; 95% CI, 0.89-0.97). The odds for postoperative inotropic support increased 2.55-times higher in patients receiving preoperative inotropic agents (OR, 2.55; 95% CI, 1.29-5.05), 2.27-times higher with renal failure (OR, 2.27; 95% CI, 1.38-3.74), and 86% higher in patients administered preoperative heparin (OR, 1.86; 95% CI, 1.14-3.02).
Mortality of surgical treatment for TVE was 4%, with higher risks with liver disease. Tricuspid valve replacement was associated with higher odds for permanent pacemaker vs repair. Renal failure, preoperative inotropic support, and preoperative heparin were associated with higher odds for postoperative inotropic support. These findings further illustrate surgical outcomes with TVE.
目前感染性心内膜炎的治疗指南主要关注左侧感染性心内膜炎。由于右侧感染性心内膜炎具有不同的表现和预后,进一步明确孤立性三尖瓣心内膜炎(TVE)的手术预后至关重要。
这项回顾性研究纳入了2012年1月至2022年4月期间374例接受孤立性三尖瓣手术治疗的孤立性TVE患者。主要结局指标为住院死亡率、永久性起搏器植入需求和术后血管活性药物支持。
住院死亡率为4%(n = 15)。与无肝病患者相比,肝病患者的死亡几率高3.81倍(比值比[OR],3.81;95%置信区间[CI],1.22 - 12.17)。在无既往起搏器植入史的患者中,17%需要植入起搏器,与三尖瓣修复相比,三尖瓣置换术后需要植入起搏器的几率高4.07倍(OR,4.07;95% CI,1.72 - 11.60)。患者年龄每增加一岁,永久性起搏器植入需求的几率降低7%(OR,0.93;95% CI,0.89 - 0.97)。接受术前血管活性药物治疗的患者术后血管活性药物支持的几率增加2.55倍(OR,2.55;95% CI,1.29 - 5.05),肾衰竭患者增加2.27倍(OR,2.27;95% CI,1.38 - 至3.74),术前接受肝素治疗的患者增加86%(OR,1.86;95% CI,1.14 - 3.02)。
TVE手术治疗的死亡率为4%,肝病患者风险更高。与三尖瓣修复相比,三尖瓣置换术后永久性起搏器植入几率更高。肾衰竭、术前血管活性药物支持和术前肝素治疗与术后血管活性药物支持几率更高相关。这些发现进一步阐明了TVE手术的预后情况。